A Phase 1 Basket Study Evaluating the Safety and Feasibility of T Plex, Autologous Customized T Cell Receptor Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Pa rticipants with Antigen positive Locally Advanced (Unresectable) or Metastatic
Contact:
NCT Number:
Protocol:
AAAU7036
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of the study is to learn if the study treatments TSC-204-A0201, TSC 200- A020, and TSC-204-C0702 alone or in combination, referred to as T-Plex, are safe and effective in treating your type of cancer. T-Plex has not yet been approved by the Food and Drug Administration (FDA). This is a first-in-human study, which means that these products have never been administered to humans before. You are unlikely to benefit from taking part in this study.
Are you Eligible? (Inclusion Criteria)
- Must be 18 years or older - Diagnosed with a locally advanced (unresectable) or metastatic solid tumor for which there are no available curative treatment options, after failure of the standard of care systemic therapies used for the treatment of recurrent (unresectable) or metastatic disease for that particular indication - Must have adequate kidney, liver, heart,and lung function
Specialty Area(s)
Colon and Rectal Cancer, Ovarian Cancer, Head and Neck/Oral Cancers, Lung cancer, Melanoma, Testicular Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
